On June 23, Argenx SE rose 3.71% in regular trading, trading at approximately $911.88 per share, with turnover of $193 million.

On the news front, BNP Paribas recently rated Argenx SE as Outperform with a price target of $1,219, implying approximately 34% upside from the current stock price. The target is notably above the analyst consensus, as FactSet data shows the stock carries an average analyst rating of Buy with a mean price target of $1,064.53. The significantly above-consensus target from BNP Paribas provided a positive boost to market sentiment surrounding the stock.

Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for the treatment of severe autoimmune diseases. Its lead product candidate, efgartigimod, targets multiple indications including myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The company last reported earnings on May 7 with EPS of $5.52, and its next earnings release is scheduled for July 23.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)